Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This early-stage study aims to test the safety and side effects of an experimental injection called SKB575. It will involve 90 participants, including healthy adults and people with moderate-to-severe atopic dermatitis (eczema). Researchers will monitor how the body processes the…

This is an early-stage study to test a new drug called SKB103 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might help shrink…

This study is testing whether two different drug treatments can safely shrink lung tumors before surgery. It is for adults with a specific type of operable non-small cell lung cancer who have not had prior cancer treatment. The goal is to see if shrinking the tumor first leads to…

This study is testing an experimental drug called SKB571 for people with advanced non-small cell lung cancer that has a specific genetic change called a MET abnormality. The trial will enroll 60 patients whose cancer has worsened after standard treatments to see if the drug is sa…

This study is testing an experimental drug called Sac-TMT for people with advanced thymic carcinoma, a rare cancer, whose disease has gotten worse after standard platinum-based chemotherapy. About 30 participants will receive the drug every two weeks to see if it shrinks their tu…

This study aims to test the safety and early effectiveness of SKB500 drug combinations in people with extensive-stage small cell lung cancer. It will enroll 80 participants to see how well the treatment controls cancer growth and how long patients live without their disease getti…

This study is testing a new drug called SKB264 for women with recurrent ovarian cancer. It aims to see if the drug helps control the cancer and checks how a common antibiotic (clarithromycin) affects the drug's levels in the body. About 20 participants will receive the drug, and …

This study is testing a new drug called SKB105 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. It will involve about 256 adult participants who have no other g…